FDA rejects Pharmacyclics cancer drug; stock plunges
December 25th, 2007
Shares of Sunnyvale-based Pharmacyclics plunged more than 26 percent Monday – the fourth-biggest drop in its history – after federal regulators refused to approve its drug Xcytrin to treat patients whose lung cancer has spread to their brain.